Altimmune (ALT)

• Market cap: $497M
• 1 day: -3.45%
• 5 days: -6.67%
• 1 month: 20.2%
• 3 months: 26.93%
• 6 months: -10.19%
• Year to date: -33.05%
• 1 year: -46.21%
• 5 years: -59.83%
• 10 years: -99.04%
• Sector: Healthcare
• Industry: Biotechnology

About: Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 59